Literature DB >> 12037780

Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance.

Albert J Czaja1.   

Abstract

Autoimmune hepatitis has been described as recurrent or de novo disease after transplantation. The legitimacy of these diagnoses and the bases for their occurrence are unknown. To better understand these aspects of allograft dysfunction, the purported pathogenic mechanisms of classical autoimmune hepatitis were reviewed and extrapolated to recurrent and de novo disease after transplantation. Loss of self-tolerance may relate to defects in the negative selection of autoreactive immunocytes and the clonal expansion of promiscuous lymphocytes that are cross-reactive to homologous antigens (molecular mimicry). Repopulation of the allograft with recipient antigen-presenting cells and the presence of primed promiscuous cytotoxic T cells within the recipient are likely factors for recurrent disease. Targets may be the same peptides that triggered the original disease, donor-derived class II antigens of the major histocompatibility complex, or homologous antigens associated with unidentified hepatotrophic viruses. De novo disease is probably due to similar mechanisms, but its predilection for children suggests that thymic dysfunction associated with cyclosporine treatment may be a factor. Corticosteroid therapy is effective in each condition. In conclusion, recurrent and de novo autoimmune hepatitis after transplantation are examples of self-intolerance. The mechanisms that perturb immunologic homeostasis in this human model of the classical disease must be studied more rigorously.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037780     DOI: 10.1053/jlts.2002.33485

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  12 in total

Review 1.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

2.  High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

Authors:  S Berardi; F Lodato; A Gramenzi; A D'Errico; M Lenzi; A Bontadini; M C Morelli; M R Tamè; F Piscaglia; M Biselli; C Sama; G Mazzella; A D Pinna; G Grazi; M Bernardi; P Andreone
Journal:  Gut       Date:  2006-06-23       Impact factor: 23.059

Review 3.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

Review 4.  Management of Difficult Cases of Autoimmune Hepatitis.

Authors:  Craig Lammert; Veronica M Loy; Kiyoko Oshima; Samer Gawrieh
Journal:  Curr Gastroenterol Rep       Date:  2016-02

Review 5.  Recurrence of autoimmune liver diseases after liver transplantation.

Authors:  Nabiha Faisal; Eberhard L Renner
Journal:  World J Hepatol       Date:  2015-12-18

Review 6.  Transplantation in autoimmune liver diseases.

Authors:  Marcus Mottershead; James Neuberger
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 7.  Pediatric liver transplantation.

Authors:  Marco Spada; Silvia Riva; Giuseppe Maggiore; Davide Cintorino; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

Review 8.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

Review 9.  Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets.

Authors:  Bin Liu; Jing Li; Lu-Nan Yan
Journal:  Clin Dev Immunol       Date:  2013-12-08

Review 10.  Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.

Authors:  Albert J Czaja
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.